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CORRELATION OF VASCULAR LEAK MEASURED USING 
GADOFOSVESET-ENHANCED LUNG MAGNETIC RESONANCE IMAGING 
WITH RADIOGRAPHIC AND PHYSIOLOGIC MEASURES OF FIBROSIS IN 
PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS 
LLOYD L LIANG 
ABSTRACT 
Idiopathic pulmonary fibrosis (IPF) is an irreversible disease of unknown etiology 
that involves progressive scarring of the lung tissue, leading to respiratory failure and 
death.1 IPF is thought to develop from repetitive lung injury and aberrant wound healing 
that leads to the generation of fibrous tissue rather than restoration of normal tissue.2 It 
has been suggested in mice that vascular leak after lung injury contributes to the 
development of lung fibrosis.2,3 Gadofosveset is an intravascular enhancing, gadolinium-
based contrast agent used with magnetic resonance imaging (MRI) to assess a variety of 
biological processes in vivo because it can reversibly bind to albumin.13-14 Gadofosveset 
has been used to assess endothelial permeability and function, as it diffuses through the 
vessel walls via leaky neovessels and damaged endothelium.15 Our research group has 
developed a new method to assess disease activity in IPF patients using gadofosveset-
enhanced lung MRI. In unpublished work, we have demonstrated that this technique can 
be used to generate an albumin extravasation index (AEI), and we have found that this is 
significantly and diffusely increased in the lung of patients with idiopathic pulmonary 
fibrosis compared to healthy controls.16 The AEI is a measure of the change in signal 
intensity post-contrast minus pre-contrast in predefined regions of interest (ROIs) in the 
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lung parenchyma divided by post- minus pre-contrast signal intensity in the ROI in the 
aorta. In this study, we compared the AEI in patients with IPF to healthy control (HC) 
subjects and evaluated the correlation between the AEI and high-resolution computed 
tomography (HRCT) and pulmonary function testing (PFT). We found that IPF subjects 
had increased AEI values compared with HC subjects. While not statistically significant, 
AEI was more strongly correlated with fibrosis (interstitial abnormalities) than ground-
glass (alveolar abnormalities) on HRCT. Furthermore, there was a possible correlation 
between AEI and change in percent predicted forced expiratory volume in the first 
second (FEV1), forced vital capacity (FVC), and diffusion capacity of carbon monoxide 
adjusted for hemoglobin (DLCO) [Hb]. Our results demonstrate that AEI calculations 
from gadofosveset-enhanced lung MRI are a surrogate measure of vascular leak and can 
potentially serve as an alternative method for predicting the clinical course and severity 
of IPF through its correlation with fibrosis on HRCT and pulmonary function.  
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INTRODUCTION 
  
 Idiopathic pulmonary fibrosis (IPF) is an irreversible disease of unknown etiology 
that involves progressive scarring of the lung tissue, leading to respiratory failure and 
death.1 The median survival for patients with IPF is 3.5 years; however, there is 
significant variability in the clinical course. Some patients have stable lung function for 
years and progress slowly over time. A subset of IPF patients experience rapid 
deterioration and death, often precipitated by acute exacerbations of the disease. 
Currently, the burden of disease due to IPF is assessed by patient-reported symptoms, 
pulmonary function testing, and high-resolution computed tomography (HRCT) of the 
chest. However, there is no test to measure ongoing fibrotic activity nor is there a method 
to reliably predict the clinical course for a given patient. The development of such a test 
would allow physicians to provide patients with more accurate prognoses, inform 
decisions regarding specific treatments and their effectiveness, and facilitate selection of 
the highest-risk patients for IPF clinical trials. 
IPF is thought to develop from repetitive lung injury and aberrant wound healing 
that leads to the generation of fibrous tissue rather than restoration of normal tissue.2 It 
has been suggested in mice that vascular leak after lung injury contributes to the 
development of lung fibrosis.2,3 More specifically, platelet products such as thrombin and 
lysophosphatidic acid (LPA) activate transforming growth factor-ß (TGF-ß) via the 
epithelial cell surface G protein coupled receptors such as LPA1.4-5 This causes increased 
epithelial cell apoptosis and transformation of fibroblasts and fibrocytes to 
myofibroblasts.4 These myofibroblasts synthesize excess and disordered collagen that is 
	2 
the hallmark of pulmonary fibrosis. In addition, matrix metalloproteinases (MMPs) and 
vascular endothelial growth factor (VEGF) have been shown to cause increased alveolar-
capillary permeability in humans by degrading extracellular matrix components in the 
interstitium.6 Levels of MMPs and VEGF positively correlate with the protein 
permeability index (PPI), calculated as the ratio of bronchoalveolar lavage fluid (BALF) 
to plasma protein, and inversely correlate with survival rates. Furthermore, IPF patients 
have significantly increased clearance of inhaled technetium 99m-labelled 
diethylenetriamine penta-acetic acid (99mTc-DTPA), reflecting increased lung epithelial 
permeability.7 Notably, the rate of 99mTc-DTPA clearance correlated with factors such as 
age, percent predicted total lung capacity (TLC), and transfer factor of the lung for 
carbon monoxide (TLCO). These clinical factors have been correlated with increased 
mortality in patients with IPF.7 Taken together, these studies suggest that abnormal 
alveolar-capillary permeability could be a potential predictor of disease progression and 
mortality in IPF. 
The ability to measure vascular leak in patients with IPF may provide useful 
information about ongoing lung injury and fibrosis. Magnetic resonance imaging (MRI) 
is a method that has recently been used to study pulmonary diseases such as cystic 
fibrosis.8-11 In addition, the development of ultrashort time-to-echo (UTE)-MRI allows 
the pulmonary parenchyma to be imaged with improved resolution and provides accurate 
assessments of pulmonary parenchymal diseases as compared to computer tomography 
(CT).12 Gadofosveset is an intravascular enhancing, gadolinium-based contrast agent 
used with MRI to assess a variety of biological processes in vivo because it can reversibly 
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bind to albumin.13-14 Gadofosveset has been used to assess endothelial permeability and 
function, as it diffuses through the vessel walls via leaky neovessels and damaged 
endothelium.15 Our research group has developed a new method to assess disease activity 
in IPF patients using gadofosveset-enhanced lung MRI. In unpublished work, we have 
demonstrated that gadofosveset-enhanced lung MRI can be used to determine an albumin 
extravasation index (AEI), which was significantly and diffusely increased in patients 
with IPF compared to healthy controls.16 The AEI is a measure of the change in signal 
intensity post-contrast minus pre-contrast in predefined regions of interest (ROIs) in the 
lung parenchyma divided by post- minus pre-contrast signal intensity in ROI in the aorta. 
In this study, we hypothesized that clinical measures of pulmonary fibrosis 
correlate to increased vascular leak as measured by AEI from gadofosveset-enhanced 
lung MRI in patients with IPF. In addition to measuring the AEI in patients with IPF and 
healthy control (HC) subjects, we correlated AEI to ground-glass scores (alveolar 
abnormalities) and fibrosis scores (interstitial abnormalities) from HRCT of patients with 
IPF. We also correlated AEI with FEV1, FVC, and DLCO values from PFT in patients 
with IPF. We found that subjects with IPF have significantly higher AEI compared to HC 
and that AEI is more strongly correlated to fibrosis scores on HRCT than to ground glass 
scores. Furthermore, we found a significant correlation between AEI and FVC in IPF 
subjects. Our data provides further evidence of the relationship between vascular leak and 
disease progression in IPF and suggests that gadofosveset-enhanced lung MRI may be a 
useful tool for predicting outcomes in patients with IPF. 
 
	4 
SPECIFIC AIMS 
1. To determine if there is increased lung vascular leak in IPF subjects compared to 
healthy control subjects as determined by AEI calculations from gadofosveset-
enhanced lung MRI. The kinetics of vascular leak as measured by gadofosveset-
enhanced MRI are not known. Thus, AEI measurements will be compared at 
multiple time points post-contrast injection. We will also compare the AEI 
between anterior and posterior regions of the lung in order to assess whether the 
AEI varies in dependent versus non-dependent areas. 
2. To compare the extent of vascular leak as determined by AEI calculations from 
gadofosveset-enhanced lung MRI with ground-glass and fibrosis scores from 
HRCT to assess whether leak is occurring in ground-glass or fibrotic areas of the 
lung. 
3. To determine if the extent of lung vascular leak correlates with disease severity 
and predicts disease progression by assessing the association between AEI and 
changes in pulmonary function. In particular, we will examine the correlation 
between overall AEI and forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC), and diffusion capacity of the lungs for carbon monoxide 
correction for hemoglobin (DLCO [Hb]) both at time of lung MRI and 6-12 
months post lung MRI.  
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METHODS 
 
Recruitment and Enrollment Methods: 
This was a Partners Human Research Committee (PHRC)/Institutional Review 
Board (IRB) approved clinical study that enrolled IPF patients from Massachusetts 
General Hospital (MGH) and healthy control (HC) volunteers using a PHRC approved 
advertisement / recruitment system called the Partners Healthcare System Research Study 
Volunteer Program (RSVP).16 Subjects met all of the inclusion and none of the exclusion 
criteria. All subjects provided written informed consent before any study procedures were 
performed. 
 
Inclusion Criteria: 
1. Group 1: Subjects with IPF (n=6) 
a. Definite or probable IPF as defined by the ATS/ERS/JRS/ALAT 
International Consensus Statement on IPF or undifferentiated interstitial 
lung disease (ILD) with possible usual interstitial pneumonia (UIP) 
pattern.17 
b. Age: 40-80 years old. 
c. Ability to give informed consent. 
d. HRCT images obtained within 6 months of gadofosveset-enhanced lung 
MR imaging. 
2. Group 2: Normal volunteers (n=4) 
a. No history of chronic pulmonary disease. 
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b. Age: 40-80 years old. 
c. Ability to give informed consent. 
d. Established primary care physician. 
 
Exclusion Criteria: 
1. History of active cardiac disease, including congestive heart failure. 
2. Pneumonia or other acute respiratory illness within 6 weeks of study entry. 
3. Cigarette smoking within 6 months of study entry. 
4. Women who are pregnant or women of childbearing potential (WOCBP). 
WOCBP excludes women over 50 years of age who had no menses in the last 2 
years and/or women who have any well-documented methods of surgical 
sterilization. Documentation of sterilization includes having had a hysterectomy 
(removal of the uterus with or without the ovaries), bilateral oophorectomy 
(removal of both ovaries), a tubal ligation (having your tubes tied), or transvaginal 
occlusion (plugging the opening of the tubes with a coil).  
5. Contraindications to MRI, including claustrophobia or seizure disorder and 
implantable devices or metal including but not limited to cardiac 
pacemaker/defibrillator, surgical clips, metal/steel valves or implants, or shrapnel. 
6. Contraindications to gadolinium-based contrast agents, including a history of 
renal insufficiency (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 
m2), or known allergy to gadolinium.  
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Because older age is a clinical feature of IPF, subjects were required to be between 40 to 
80 years of age.1 History of active cardiac disease, pneumonia, and acute respiratory 
illness were exclusions because they may contribute to vascular leak.1,18 Patients with 
smoking history within the last 6 months were excluded because it is known that smokers 
have increased vascular leak when compared to nonsmokers.19 An eGFR less than 60 
mL/min/1.73 m2	was set to ensure a safe elimination rate of the gadolinium-based 
contrast agent.20 
 
Study Visit and Data Collection: 
Subjects were administered gadofosveset trisodium (Ablavar®, Lantheus Medical 
Imaging), an FDA-approved, gadolinium-based MR contrast agent, in a single 
intravenous injection at the recommended dose of 0.03 mmol/kg of body weight.16 Lung 
MRI images were acquired using commercial, FDA-approved 3 Tesla MRI scanners 
(PRISMA, Siemens Medical) with an 18-channel body array and 12 channels of a spine 
array using a pointwise encoding time reduction with radial acquisition (PETRA) with a 
flip angle of 25, TE 50 microseconds, 40K radials, 3D field of view of 400mm, and pixel 
resolution of 1.56 x 1.56 x 1.56mm. All images were acquired while subjects were free 
breathing. Baseline images were performed prior to gadofosveset trisodium 
administration, immediately following a single injection of the MR contrast (vascular 
phase), and every 2.5 – 5 minutes up to 35 minutes post-injection (delayed phase). 
 Demographic and clinical data for IPF patients were recorded in a password-
protected database supported by Partners Healthcare. Specifically, we recorded age, 
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gender, race/ethnicity, smoking status, and serial measurements of pulmonary function 
(FEV1, FVC, DLCO [Hb]). For HC subjects, only demographic information was 
recorded. 
 
MR Image Analysis and AEI Calculation: 
MR images were first extracted and analyzed using the freeware Dicom reader 
Osirix (www.osirix-viewer.com).16 Using this program, ROIs were drawn in the aortic 
arch in the upper axial sections, superior vena cava, ascending and descending aorta, 
main pulmonary artery, and left and right pulmonary artery in the middle axial sections, 
and descending aorta in the lower axial sections (Fig. 1, red circles). These ROI were 
used to determine gadofosveset steady state in the blood and for normalization of lung 
measurements. In addition, 18 lung ROIs were drawn in the subpleural regions on axial 
images of the upper (Fig. 1A), middle (Fig. 1B) and lower (Fig. 1C) lungs zones. Axial 
regions were further divided into left and right, as well as anterior (blue circles), medial 
(green circles), and posterior (yellow circles) in the coronal plane. The size of the ROIs 
was standardized and ROIs were positioned to minimize inclusion of large blood vessels. 
ROI placement was verified by two licensed radiologists. 
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Figure 1. Regions of 
Interest (ROIs) on axial 
lung cuts from an IPF 
subject. A. upper, B. middle, 
and C. lower lung regions.  
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An AEI was calculated as the change in lung signal intensity post-contrast minus 
pre-contrast normalized to the change in signal intensity in the aorta as follows: 
 AEI = (lung	signal	intensity	postcontrast − precontrast)(aorta	signal	intensity	postcontrast − precontrast) 
 
AEI were calculated at baseline (pre-contrast), immediately post-contrast (time 0) and at 
for each image series between 10 and 20 minutes post-contrast for all subjects. Regional 
AEI in the axial plane were calculated by averaging the right- and left-sided values in 
each coronal plane as follows: 
AEI7897: = AEI7;<=>9?> + AEIA=B97: + AEIC?D<=>9?>6  
 
Regional AEI in the coronal plane were calculated by averaging the right- and left-sided 
values in each axial plane as follows: 
AEIF?>?;7: = AEIGCC=> + AEIA9BB:= + AEI:?H=>6  
 
Total AEI was calculated by averaging the AEI for all 18 ROI. 
Gadofosvoset steady-state in the blood was determined to be between 10 and 20 
minutes post-contrast injection.16 Thus, we used the average of the total AEI between 
12.5 and 17.5 minutes (AEI12.5-17.5) for comparison of groups and correlation with HRCT 
and PFT measurements. 
The kinetics of vascular leak in the lung as measured by gadofosveset-enhanced 
MRI are not known. Thus, we compared the total AEI immediately post-contrast 
injection (0 minutes), 10 – 12.5 minutes post-contrast injection, and 15 – 20 minutes 
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post-contrast injection. For subjects that had more than one AEI measurement per time 
range, we used the earliest one for analysis. In addition, the rate of change in total AEI 
per minute from 0 – 12.5 minutes (R1) and 12.5 – 17.5 minutes (R2) were calculated as 
follows: 
R1 = AEIKL.N − AEIO12.5  
and 
R2 = AEIKR.N − AEIKL.N5  
 
Rates of change in total AEI were compared between HC and IPF subjects. 
 
HRCT Scoring and Correlation with AEI Measurements: 
HRCT scans were reviewed and scored by two experienced thoracic radiologists 
at MGH, who were blinded to the subjects’ identity, clinical, physiologic, and pathologic 
parameters. Utilizing a previously developed and validated radiologic scoring system, 
alveolar and interstitial abnormalities on HRCT images were scored on a scale of 0-5 at 
three levels, upper (aortic arch), middle (carina), and lower (1 cm above the diaphragm) 
for both left and right lungs.21 Alveolar abnormalities (ground-glass score) were 
characterized by ground-glass opacity while interstitial abnormalities (fibrosis score) 
were characterized by honeycombing and reticulation. The scores for each region of the 
lung were averaged for the two readers prior to analysis. For scores with discrepancies 
>1, the principal investigator served as a tiebreaker. Scores of 0 were considered normal 
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for alveolar abnormalities and scores of 1-5 were considered abnormal. For fibrosis 
scores, 0-1 were considered normal for interstitial abnormalities and 2-5 were considered 
abnormal. The HRCT scoring system for IPF is shown below in Table 1. 
 
Table 1. Thin-Section CT Scoring Criteria for Idiopathic Pulmonary Fibrosis.20 
 
Score Features 
Ground-glass 
score 
 
0 No ground glass opacity 
1 Ground glass opacity involving ≤5% of the section (minimal, but not normal) 
2 Ground glass opacity involving 5 – 25% of the section 
3 Ground glass opacity involving 25 – 49% of the section 
4 Ground glass opacity involving 50 – 75% of the section 
5 Ground glass opacity involving ≥75% of the section 
Fibrosis score  
0 No fibrosis 
1 Interlobular septal thickening; no discrete honeycombing 
2 Honeycombing (with or without septal thickening) involving <25% of the section 
3 Honeycombing (with or without septal thickening) involving 25 – 49% of the section 
4 Honeycombing (with or without septal thickening) involving 50 – 75% of the section 
5 Honeycombing (with or without septal thickening) involving ≥75% of the section 
 
The ground glass and fibrosis scores from all 6 HRCT regions were averaged and 
correlated to total AEI for subjects with IPF. 
 
Correlation of PFT and AEI Measurements: 
Finally, physiological measurements obtained via PFTs in 5 IPF subjects ± 3 
months from baseline and 6-12 months after the gadofosveset-enhanced lung MRI was 
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performed were obtained. The difference in the PFT measurements between time points 
were correlated with the total AEI12.5-17.5. More specifically, we correlated total AEI12.5-
17.5 with the absolute and percent predicted FEV1, FVC and DLCO [Hb]. 
 
Biostatistical Analysis: 
Statistical analyses were performed using Prism 7.0. For all analyses, results were 
considered significant when p < 0.05. Based on the very small sample size, we did not 
assume normal distribution. Unpaired nonparametric Mann Whitney t-test was used to 
assess for differences in the AEI between IPF and HC subject groups. Two-way ANOVA 
was used to assess AEI measurements at time points (0, 10-12.5, 15-20 minutes) post-
contrast injection as well as to compare the rate of change in AEI from 0 to 12.5 minutes 
and from 12.5 to 17.5 minutes. Linear regression was used to correlate total AEI12.5-17.5 
and ground-glass and fibrosis scores as well as total AEI12.5-17.5 and change in pulmonary 
function over 6-12 months. 	  
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RESULTS 
 
Subject Characteristics: 
Six subjects were enrolled in the IPF group, and four subjects were enrolled in the 
HC group. Relevant demographic and clinical data are summarized in Table 2. In the IPF 
group, 5 subjects met diagnostic criteria as defined by the ATS/ERS/JRS/ALAT 
International Consensus Statement on IPF,17 and one subject was diagnosed with yet to 
be differentiated ILD with a possible UIP pattern. The mean age for IPF subjects was 
68.7 years and for healthy control subjects was 61.8 years. 
 
Table 2. Characteristics of Subjects.  
 
 IPF (n=6) HC (n=4) 
Age (years) 68.7 ± 4.2 61.8 ± 8.8 
Sex (M/F)* 4/2 4/0 
Smoking (Ever/Never)* 4/2 1/3 
IPF = idiopathic pulmonary fibrosis. HC = healthy control.  
Values are expressed as mean ± standard deviation unless otherwise noted. 
*Values are expressed as numbers of subjects. 
 
 
Spirometry measurements were available for five IPF subjects; however, diffusion 
measurements were only available for four IPF subjects. Difference in pulmonary 
function tests obtained within ± 1 month of MR imaging (baseline) and 6-12 months after 
MR imaging were calculated. These results are summarized in Table 3. 
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Table 3. Pulmonary Function Measurements for IPF Subjects.  
 
 Baseline (n=5) 
Post 6-12 months 
(n=5) 
Difference 
(n=5) 
FEV1 (L) 2.06 ± 0.30 1.92 ± 0.40 -0.14 
FEV1 (% predicted) 77.0 ± 9.90 74.4 ± 15.3 -2.60 
FVC (L) 2.51 ± 0.43 2.34 ± 0.54 -0.17 
FVC (% predicted) 73.4 ± 13.2 70.8 ± 18.1 -2.60 
DLCO [Hb] 
(mL/min/mmHg)* 11.2 ± 0.95 11.0 ± 2.62 -0.18 
DLCO [Hb] (% predicted)* 50.8 ± 5.56 49.8 ± 8.18 -1.00 
FEV1 = forced expiratory volume in one second. FVC = forced vital capacity. DLCO [Hb] = diffusion 
capacity of lungs for carbon monoxide when corrected for hemoglobin.  
All values are expressed as mean ± standard deviation. 
* n=4 subjects 
 
 
Albumin Extravasation Indices (AEI) for IPF and HC Subjects: 
Subjects with IPF had higher total AEI12.5-17.5 compared to HC subjects (0.42 ± 
0.10 vs. 0.11 ± 0.19, p < 0.01) as shown in Table 4 and Fig. 2A. Axial AEI12.5-17.5 was 
also increased in the upper, middle and lower lung regions in IPF subjects as compared to 
HC subjects (0.44 ± 0.16 vs. 0.14 ± 0.19, p < 0.05, 0.43 ± 0.10 vs. 0.12 ± 0.22, p < 0.01, 
and 0.39 ± 0.08 vs. 0.07 ± 0.18, p < 0.01, respectively) as shown in Table 4 and Fig. 2B. 
Although there was a trend toward a higher coronal AEI12.5-17.5 in the anterior and medial 
regions in IPF subjects compared to HC, these were not significant (0.40 ± 0.17 vs. 0.08 
± 0.29, p = 0.11, 0.28 ± 0.09 vs. 0.08 ± 0.12, p = 0.07, respectively). However, IPF 
subjects had higher coronal AEI12.5-17.5 in the posterior region compared to HC subjects 
(0.58 ± 0.14 vs. 0.18 ± 0.20, p < 0.01; Table 4 and Fig. 2D). We compared the AEI 
across axial sections in HC to determine whether there are regional variations in vascular 
leak in normal lung tissue. However, there were no significant differences in AEIupper vs. 
AEImiddle vs. AEIlower. Although we predicted that subjects with IPF would have higher 
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AEIlower compared to other axial regions, there were also no significant differences in the 
IPF group. Finally, we compared AEI across coronal regions of the lung to determine 
whether vascular leak varied in dependent vs. non-dependent lung. While not significant, 
the AEIposterior was greater than the AEIanterior for both IPF and HC subjects. 
 
 
 
Figure 2. Albumin Extravasation Indices (AEI). A. Total AEI12.5-17.5  B. AEI for upper, 
middle, and lower axial lung regions C. AEI for anterior, medial, and posterior coronal 
lung regions. Data are displayed as mean ± standard deviation. Blue dots (●) represent 
individual healthy controls and red diamonds (◆) represent individual IPF subjects. *p < 
0.05, **p < 0.01 
 
 
 
Table 4. Albumin Extravasation Indices (AEI).  
 
 IPF (n=6) HC (n=4) p-value 
Total AEI12.5-17.5 0.42 ± 0.10 0.11 ± 0.19 0.0095 
Axial AEI12.5-17.5:    
Upper 0.44 ± 0.16 0.14 ± 0.19 0.0381 
Middle 0.43 ± 0.10 0.12 ± 0.22 0.0095 
Lower 0.39 ± 0.08 0.07 ± 0.18 0.0095 
Coronal AEI12.5-17.5:    
Anterior 0.40 ± 0.17 0.08 ± 0.29 0.1143 
Medial 0.28 ± 0.09 0.08 ± 0.12 0.0667 
Posterior 0.58 ± 0.14 0.18 ± 0.20 0.0095 
IPF = idiopathic pulmonary fibrosis. HC = healthy control.  
All values are mean ± standard deviation. 
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AEI Comparison Between Multiple Time Points Post-Contrast Injection: 
 
 IPF subjects had higher total AEI12.5-17.5 measurements at both 10-12.5 and 15-20 
minutes post-contrast injection compared with HC subjects (p < 0.01 and p < 0.01, 
respectively).  
 
 
Figure 3. AEI comparison between multiple time points post-contrast injection. 
Pre-contrast = 0 minutes, First post-contrast range = 10-12.5 minutes post-contrast 
injection, and Second post-contrast range = 15-20 minutes post-contrast injection. 
 
 
 
There was no difference in the R1 (rate of change in total AEI12.5-17.5 between 0-12.5 
minutes) for IPF compared to HC subjects (0.03 ± 0.01 vs. 0.01 ± 0.01, p = 0.50). 
However, IPF subjects had a higher R2 (rate of change in total AEI12.5-17.5 between 12.5-
17.5 minutes) compared to HC subjects (0.03 ± 0.03 vs. -0.01 ± 0.02, p < 0.05). 
 
	18 
 
Figure 4. Rate of Change in AEI. 
R1 = rate of change in AEI between 0-12.5 minutes, R2 = rate of change in AEI between 
12.5-17.5 minutes 
 
 
Correlation Between AEI and HRCT Scores: 
Although they did not reach statistical significance, we found a positive 
correlation between total AEI12.5-17.5 and ground-glass and fibrosis scores on HRCT in 
IPF subjects (R = 0.80, p = 0.20 and R = 0.89, p = 0.11, respectively) as shown in Fig. 5. 
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Figure 5. Correlation between total AEI and HRCT scores. A. mean ground-glass 
score and B. mean fibrosis score. 
 
 
Correlation between AEI and Pulmonary Function Change over 6-12 months: 
 We did not find a statistically significant correlation between total AEI12.5-17.5 and 
any of the pulmonary function measurements including change in absolute FEV1, 
absolute FVC, absolute DLCO [Hb], percent predicted FEV1, percent predicted FVC, or 
percent predicted DLCO [Hb]. Correlation between total AEI12.5-17.5 and the change in 
percent predicted FEV1, percent predicted FVC, and percent predicted DLCO [Hb] (R = 
0.42, p = 0.48; R = 0.51, p = 0.38; R = 0.66, p = 0.34, respectively) as shown in Fig. 6A-
C. One subject demonstrated outlier behavior that skewed the data. When this subject’s 
PFT data was excluded from the linear regression analysis, the total AEI was negatively 
correlated with change in percent predicted FEV1, percent predicted FVC, and percent 
predicted DLCO [Hb], though these did not reach statistical significance (R = 0.91, p = 
0.09; R = 0.93, p = 0.07; R > 0.99, p = 0.06, respectively). 
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Figure 6. Correlation between AEI and Change in PFT Percent Predicted 
Measurements over 6-12 months. A. Difference in FEV1 % predicted, B. Difference in 
FVC % predicted and C. Difference in DLCO [Hb] % predicted. 
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DISCUSSION 
 
This study used gadofosveset-enhanced lung MRI, a novel imaging technique, to 
assess vascular leak in patients with IPF and correlate these findings with alveolar and 
interstitial abnormalities on HRCT as well as physiological measures of lung function 
determined by PFTs. We demonstrated that IPF subjects had increased vascular leak, as 
measured by AEI, compared to HC subjects. In addition, the rate of change in vascular 
leak was significantly higher in IPF subjects between 12.5 to 17.5 minutes post-contrast 
administration as compared to HC subjects, consistent with ongoing vascular leakage due 
to increased alveolar capillary permeability. While not significant, there was a stronger 
correlation between total AEI12.5-17.5 and fibrosis (interstitial abnormalities) than ground-
glass (alveolar abnormalities) on HRCT. Furthermore, we demonstrated that total AEI12.5-
17.5 is negatively correlated with the change in percent predicted FEV1, FVC, and DLCO 
[Hb], when excluding the IPF subject’s PFT data that demonstrated outlier behavior. 
These results suggest that determination of the magnitude of vascular leak could be a 
useful tool to predict the clinical course and severity of disease in IPF patients. 
Vascular leak has been shown to play a significant role in the fibrogenic response 
to lung injury in mice,3 and previous studies have provided evidence for increased 
alveolar capillary permeability in patients with IPF.6,7 Furthermore, alveolar capillary 
permeability correlated with survival, suggesting that measuring the degree of alveolar 
capillary permeability may be an important prognostic tool for patients with IPF. The 
albumin-binding contrast agent gadofosveset has previously been used as a non-invasive 
assessment of endothelial permeability in mouse models of atherosclerosis.15 In this 
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model, quantification of vascular leak using gadofosveset-enhanced MRI correlated with 
detection of morphological changes in endothelial cells and widening of cell-cell 
junctions measured with Evans blue staining. Additionally, gadofosveset-enhanced MRI 
was able to detect improvements in leak across gap junctions after administration of 
therapies with atheroprotective effects.22 This data suggests that gadofosveset-enhanced 
MRI can be used as a noninvasive monitor for changes in endothelial permeability. 
However, gadofosveset-enhanced MRI had not been applied to human lung disease until 
recently.16 In the current study, we used an overlapping cohort of patients but a different 
methodology for calculating AEI. Specifically, we used defined ROI rather than whole 
lung measures and slightly different time points to calculate AEI. Our findings are 
consistent with the prior analysis and demonstrated that total AEI12.5-17.5 is significantly 
higher in IPF subjects compared to HC subjects.16 
In current clinical practice, disease severity in IPF is measured with HRCT and 
PFTs. These tests measure the radiographic extent of established fibrosis and the 
physiologic impairment caused by the disease, respectively. However, neither test 
assesses the activity of pathological processes leading to disease progression. 
Gadofosveset-enhanced MRI has the potential to image vascular leak at a molecular level 
while simultaneously providing information about structural changes in the lung 
parenchyma.16 The use of AEI as a surrogate for vascular leak in this study allowed us to 
answer important questions about regional vascular leak. First, we found that IPF subjects 
had a similar degree of vascular leak in upper, middle and lower lung regions, suggesting 
that vascular leak is uniform across axial lung regions in IPF. This finding is interesting 
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for several reasons. First, it suggests that there is a diffuse pulmonary endothelial 
abnormality in patients with IPF. Second, it implies that the basilar predominance of 
fibrotic changes may reflect an additional insult in this region, such as tractional stress.23 
We also demonstrated that, in the supine position, vascular leak is greater in posterior 
(dependent) lung regions compared to anterior (non-dependent) regions in both IPF and 
HC subjects. Posterior regions of the lung are susceptible to atelectasis, which has been 
shown to cause increased lung permeability by reducing local alveolar oxygen tension 
and disruption of the vascular endothelium.24 Furthermore, posterior regions of the lung 
are the most susceptible to gravitational effects, which would move any vascular leak 
occurring to this region of the lung, increasing the AEI.  
Honeycombing and reticular abnormalities on CT images have been shown to 
correlate with fibrosis on biopsy specimens.20 Although not statistically significant, the 
total AEI12.5-17.5 was positively correlated with fibrosis scores from HRCT, and to a lesser 
extent, ground-glass scores. Furthermore, we found a possible non-significant, negative 
correlation between total AEI12.5-17.5 and the change in percent predicted FEV1, FVC, and 
DLCO [Hb] when excluding the IPF subject’s PFT data that appeared to skew the 
correlation. Although these findings would need to be replicated in a larger cohort, they 
suggest that measuring AEI with gadofosveset-enhanced MRI may provide clinically 
relevant information about the pathological and physiological changes in IPF, which in 
turn are linked to important patient outcomes.5 It is important to note that our AEI 
measurements preceded the changes measured in PFTs, suggesting that AEI captures an 
ongoing pathological process at the molecular level. 
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Despite promising evidence in support of this novel imaging technique, there are 
several limitations to our study. The major limitation is our small sample size, which 
limited our ability to detect true difference between groups. We were unable to enroll 
additional subjects due to the discontinuation of gadofosveset by the manufacturer. This 
discontinuation further limits our study as it precludes validated in a larger cohort. 
However, alternative MR-based methods exist that hold promise for measuring vascular 
leak in IPF. T1-weighted dynamic contrast-enhanced MR imaging, which measures 
contrast agent kinetics to identify structural and functional changes in the pulmonary 
microvasculature and has been applied to image asthma patients,25 is currently being 
studied in IPF patients. Additionally, IPF and HC subjects were not matched for smoking 
history. We do not believe this significantly affected our results as previous studies have 
shown that pulmonary epithelial permeability is reversible and rapidly decreased within a 
week after discontinuation of smoking.19 Finally, vascular leak is not specific to 
pulmonary fibrosis and can be observed in several diseases including congestive heart 
failure, pneumonia and other acute respiratory illnesses. However, the inclusion and 
exclusion criteria for this study were designed to avoid enrolling patients with these 
conditions.1,18 
 In summary, this study provided additional support for the use of AEI 
measurements as a surrogate for vascular permeability and addressed whether AEI is 
correlated with measures of alveolar and interstitial abnormalities on HRCT in subjects 
with IPF. In addition, correlations between vascular leak and physiological measures, as 
determined by PFTs, in IPF subjects were identified. MR-based imaging techniques to 
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measure vascular leak in patients with IPF have great potential, but further research is 
needed. The ability to measure an active process contributing to fibrosis pathogenesis, 
rather than the established fibrosis measured by current clinical tests, would be a 
substantial advance in the care of patients with IPF. This type of imaging may allow for 
more accurate prediction about the clinical course of IPF, inform decisions regarding 
specific treatments and their effectiveness, and improved selection of the highest-risk 
patients for IPF clinical trials.	  
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